Skip to content
ContentLora

    Tip: press / anywhere to search.

    Explainer

    PDUFA dates explained: how FDA review deadlines work

    A PDUFA date is the goal date by which FDA aims to act on a drug or biologic application under the Prescription Drug User Fee Act, the 1992 law that funds reviews through company fees.[1][2] For new molecular entities, FDA aims to act on 90% of applications within 10 months of the 60-day filing date, or 6 months under Priority Review.[3] A major amendment can push the date back three months, and acting can mean an approval or a letter listing the deficiencies.[4][2]

    Editor reviewedUpdated Explainer14 claims · 100% primaryHealth and medicine, Statistics and evidence

    This page explains FDA review deadlines. It is not medical advice or investment advice. For what a specific medicine is approved for, see its FDA label or ask a health professional.

    A PDUFA date is the deadline FDA sets itself for deciding on a new drug or biologic application. The Prescription Drug User Fee Act (PDUFA), created by Congress in 1992, lets FDA collect fees from companies that submit certain drug applications; it must be reauthorised every five years, and the current version, PDUFA VII, runs through September 2027.[1] Under the law, FDA also agreed to review-time goals.[5] The full approval process is covered in how FDA drug approval works.

    Where the date comes from

    In 1992 FDA created a two-tier system of Standard Review and Priority Review.[5] FDA tells a company within 60 days of receiving an original application whether it has Priority Review.[6]

    For new molecular entity NDAs and original BLAs, the review clock starts when the 60-day filing review period ends.[7] FDA then aims to act on 90% of standard applications within 10 months of that filing date, and on 90% of priority ones within 6 months.[3] For other original NDAs, the clock runs from receipt: 10 months for standard and 6 months for priority applications.[8]

    Priority Review goes to drugs that would significantly improve the treatment, diagnosis or prevention of serious conditions, and it does not lower the standard of evidence for approval.[9]

    Milestones before the date

    Under PDUFA VII, FDA’s Day 74 letter for these applications gives the planned date of its internal mid-cycle review and says whether it expects to hold an advisory committee meeting.[10] When no advisory committee is planned, the late-cycle meeting generally takes place at least 3 months before the goal date for a standard review, or 2 months for a priority review.[10]

    What can move the date

    A major amendment to an application, submitted at any point in the review, may extend the goal date by three months.[4] Examples include a major new clinical safety or efficacy study report or a major re-analysis of studies already submitted.[4]

    What happens on the date

    The commitment is to “review and act on” an application, which means issuing a complete action letter after a full review.[2] If that letter is not an approval, it sets out the deficiencies and, where appropriate, what the company must do to make the application approvable.[2]

    A company can answer with a resubmission that responds to every deficiency.[11] FDA aims to act on 90% of Class 1 resubmissions, which are limited to items such as labeling and safety updates, within 2 months, and on 90% of Class 2 resubmissions within 6 months.[11][8]

    Examples from November 2026

    The examples below come from company announcements, and this page does not report the outcomes of these reviews. Summit said its application for ivonescimab in a form of non-small cell lung cancer had a PDUFA goal date of 14 November 2026.[12] Sanofi said the FDA gave venglustat Priority Review in type 3 Gaucher disease with a target action date of 25 November 2026.[13] The povetacicept application for IgA nephropathy was under Priority Review with a target action date of 30 November 2026.[14]

    Povetacicept

    Povetacicept is Vertex's BAFF and APRIL inhibitor for IgA nephropathy. Its trials and the FDA decision due 30 November 2026.

    More in Health & medicine

    Questions readers ask

    What is a PDUFA date?

    It is the goal date for FDA to review and act on a drug or biologic application under the Prescription Drug User Fee Act. Acting means issuing a complete action letter after a full review.[1][2]

    How long does an FDA review take?

    Under PDUFA VII, FDA aims to act on 90% of standard new molecular entity NDAs and original BLAs within 10 months of the 60-day filing date, and on 90% of priority ones within 6 months of that date. That is about 12 months, or 8 months, after FDA receives the application.[3][7]

    What is Priority Review?

    It is a designation for drugs that would significantly improve the treatment, diagnosis or prevention of serious conditions. FDA aims to act within 6 months instead of 10, and the standard of evidence for approval does not change.[9]

    Can a PDUFA date change?

    Yes. A major amendment, such as a major new clinical study report or a major re-analysis of earlier studies, may extend the goal date by three months.[4]

    Does a PDUFA date mean the drug will be approved?

    No. The date is when FDA aims to act. If the action letter is not an approval, it sets out the deficiencies and, where appropriate, what the company must do.[2]

    What happens after a rejection?

    The company can resubmit with a complete response to the letter. FDA aims to act on 90% of Class 1 resubmissions within 2 months and Class 2 resubmissions within 6 months.[11][8]

    Sources

    · 14 claims from 4 publishers

    Each numbered claim is a statement we checked against the sources listed with it. Tap a number in the text to see its sources in place.

    1. [1]

      The Prescription Drug User Fee Act (PDUFA), created by Congress in 1992, lets FDA collect fees from companies that submit certain drug applications; it must be reauthorised every five years, and the current version, PDUFA VII, runs through September 2027. confirmedas of 2026-11-07

    2. [2]

      In the PDUFA VII commitment letter, "review and act on" means issuing a complete action letter after a full review; if the letter is not an approval, it sets out the deficiencies and, where appropriate, what is needed to make the application approvable. confirmedas of 2026-11-14

    3. [3]

      Under PDUFA VII, FDA commits to review and act on 90% of standard new molecular entity NDAs and original BLAs within 10 months of the 60-day filing date, and 90% of priority ones within 6 months of that date. confirmedas of 2026-11-07

    4. [4]

      Under PDUFA VII, a major amendment to an original application, efficacy supplement or resubmission, such as a major new clinical safety or efficacy study report or a major re-analysis of earlier studies, may extend the goal date by three months. confirmedas of 2026-11-14

    5. [5]

      Under PDUFA in 1992, FDA agreed to review-time goals and created a two-tier system of Standard Review and Priority Review. confirmedas of 2026-11-07

      • Priority Review · US Food and Drug Administration · Primary source (retrieved 2026-11-07)
    6. [6]

      FDA tells an applicant within 60 days of receiving an original NDA, BLA or efficacy supplement whether it has Priority Review. confirmedas of 2026-11-07

      • Priority Review · US Food and Drug Administration · Primary source (retrieved 2026-11-07)
    7. [7]

      For new molecular entity NDAs and original BLAs, the PDUFA VII commitment letter says the review clock begins when the 60-day filing review period, which starts on the day FDA receives the application, ends. confirmedas of 2026-11-14

    8. [8]

      Under PDUFA VII, FDA aims to act on 90% of standard non-NME original NDAs within 10 months of receipt and 90% of priority ones within 6 months, and on 90% of Class 1 resubmissions within 2 months and Class 2 resubmissions within 6 months of receipt. confirmedas of 2026-11-14

    9. [9]

      Priority Review means FDA aims to act on an application within 6 months instead of 10 under standard review; it goes to drugs that would significantly improve the treatment, diagnosis or prevention of serious conditions, and it does not lower the standard of evidence for approval. confirmedas of 2026-11-07

      • Priority Review · US Food and Drug Administration · Primary source (retrieved 2026-11-07)
      • Priority Review · US Food and Drug Administration · Primary source (retrieved 2026-11-07)
      • Priority Review · US Food and Drug Administration · Primary source (retrieved 2026-11-07)
    10. [10]

      Under PDUFA VII, FDA's Day 74 letter for new molecular entity and original biologic applications gives the planned mid-cycle review date and preliminary plans on holding an advisory committee meeting, and without an advisory committee the late-cycle meeting generally takes place at least 3 months (standard review) or 2 months (priority review) before the PDUFA goal date. confirmedas of 2026-11-14

    11. [11]

      Under PDUFA VII, a resubmitted application is a complete response to an action letter that addresses all the deficiencies, and a Class 1 resubmission is one limited to items such as labeling, safety or stability updates, Phase 4 commitments or assay validation data. confirmedas of 2026-11-14

    12. [12]

      In January 2026 the FDA accepted Summit's Biologics License Application for ivonescimab plus chemotherapy in EGFR-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer after EGFR tyrosine kinase inhibitor therapy, with a PDUFA goal date of 14 November 2026. confirmedas of 2026-11-04

    13. [13]

      On 28 May 2026 Sanofi announced that the FDA had granted priority review to its new drug application for venglustat in type 3 Gaucher disease, with a target action date of 25 November 2026. confirmedas of 2026-05-28

    14. [14]

      As of November 2026 the povetacicept application for accelerated approval in IgA nephropathy was under FDA priority review with a target action date of 30 November 2026, supported by a pre-specified week-36 interim analysis of the ongoing phase 3 RAINIER trial. confirmedas of 2026-11-02

    Revision history (1)
    1. Page created.

    Created Nov 14, 2026. Last reviewed by an editor on Nov 15, 2026. Next scheduled review: Nov 14, 2028.

    Cite this page

    "PDUFA dates explained: how FDA review deadlines work." ContentLora, updated Nov 14, 2026. https://contentlora.com/explain/fda-pdufa-dates-explained

    Spotted an error? Suggest a correction or emailcorrections@contentlora.com.